Genenta Announces 20 million ($20.9M) Financing to Expand Pipeline As Brain Tumor Trial Is Showing Promising Survival Rates Milan, Italy and New York, USA

Announces 20 million ($20.9M) Financing to Expand Pipeline As Brain Tumor Trial Is Showing Promising Survival

Italy and New York, USA - March 19, 2025 - Genenta Science (Nasdaq: GNTA), a pioneer in immuno-oncology and a leader in cell-based

therapeutics, today announced a 20 million ($20.9 million) financing through the issuance of a Mandatory Convertible

Bond to ENEA Tech and Biomedical (ETB) to support the expansion of its pipeline by advancing Temferon in metastatic Renal Cell Cancer

(mRCC). ETB is a leading private foundation, supervised by the Italian Ministry of Enterprises and Made in Italy, managing over 1.7

billion in assets under management through two funds. With deep expertise in the biomedical sector, ETB is an established authority in

identifying and supporting high-potential biotech companies.

conducted a deep and thorough scientific and legal due diligence before committing to this investment. We spent several months in negotiations,"

said Pierluigi Paracchi, CEO of Genenta. "We believe the mandatory convertible bond terms are indicative of the potential

long-term value of Genenta's shares. The bond will not result in immediate dilution to Genenta's shareholders and is

expected to provide the necessary capital to achieve key milestones in the Company's new mRCC trial. Conversion to equity is set

for March 2028, followed by a two-year lock-up period. Naturally, the process will be accelerated in the event of a change of control

of our Company. ETB is a trusted partner with strong financial backing, which will help ensure the financial stability required to

advance the validation of the Temferon platform and our ability to pursue strategic collaborations."

February data cutoff from the Phase 1/2a Glioblastoma Multiforme (GBM) uMGMT trial shows an increase in the percentage

of patients surviving at two years, now reaching 29%, compared to 25% in October. Additionally, there is a marginal improvement in median

overall survival, which now stands at 17 months. Historically reported data showed the overall survival of uMGMT patients undergoing

standard of care to be approximately 14% at two years with a median overall survival of 13-15 months.

the Phase 1/2a trial in metastatic Renal Cell Carcinoma has recently begun enrolling patients, further strengthening the Company's

clinical pipeline for Temferon.

Luigi Naldini, Co-founder of Genenta, added: "We are continuing to demonstrate at pre-clinical and clinical levels Temferon's

ability to reprogram the tumor microenvironment, which in turn induces cell-mediated immune responses, as suggested by

Genenta's ongoing GBM trial and which will be under testing in the Company's mRCC trial."

Mandatory Convertible Bond Investment Terms:

The information provided herein regarding the Mandatory Convertible Bond is a summary and does not purport to be comprehensive. The full

terms and conditions of the Mandatory Convertible Bond are set forth in the official subscription agreement by and between Genenta and

ETB and relevant bond regulations, which are detailed and govern the issuance of the Mandatory Convertible Bond. Investors are encouraged

to refer to the full documentation. The complete documentation with respect to the Mandatory Convertible Bond is available in the Company's

Form 6-K filing with the SEC filed concurrently with this press release and on the Company's website at www.genenta.com.

(Nasdaq: GNTA) is a clinical stage immuno-oncology company developing a proprietary hematopoietic stem cells therapy for the treatment

of a variety of solid tumor cancers. Genenta first in class product candidate is Temferon , which is designed to allow the expression

of immune-therapeutic payloads within the tumor microenvironment by bone marrow derived myeloid cells and enable a durable and targeted

response. Genenta has completed the Phase 1 trial for newly diagnosed Glioblastoma Multiforme patients with an unmethylated MGMT gene

promoter, which suggests the potential reprogramming of the tumor microenvironment and inhibiting of myeloid induced tolerance, while

allowing the induction of T cell responses, potentially breaking immune tolerance. Genenta has initiated in Q4 2024 a Phase 1/2a metastatic

Renal Cell Carcinoma study that will also include a combination with immune checkpoint inhibitors. Genenta's treatments are designed

as one-time monotherapies, but with the additional potential, when used in combination, to significantly enhance the efficacy of other

approved therapeutics.

in this press release contain "forward-looking statements," within the meaning of the U.S. Private Securities Litigation

Reform Act of 1995, that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact,

contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified

by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate,"

"expect," "intend," "seek," "may," "might," "plan," "potential,"

"predict," "project," "suggest," "target," "aim," "should," "will,"

"would," or the negative of these words or other similar expressions, although not all forward-looking statements contain

these words. Forward-looking statements are based on Genenta's current expectations and are subject to inherent uncertainties,

risks and assumptions that are difficult to predict, including risks related to the funding to be provided by the Mandatory Convertible

Bond, the completion and timing of Genenta's ongoing clinical trial for newly diagnosed GBM patients with uMGMT-GBM, its clinical

trial for metastatic RCC or any related studies, as well as Genenta's ability to fund its research and development plans. Further,

certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks

and uncertainties are described more fully in the section titled "Risk Factors" in Genenta's Annual Report on Form

20-F for the year ended December 31, 2023 filed with the Securities and Exchange Commission. Forward-looking statements contained in

this announcement are made as of the date of this announcement, and Genenta undertakes no duty to update such information except as required

under applicable law. This press release discusses product candidates that are under preclinical or clinical evaluation and that have

not yet been approved for marketing by the U.S. Food and Drug Administration or any other regulatory authority. Until finalized in a

clinical study report, clinical trial data presented herein remain subject to adjustment as a result of clinical site audits and other

review processes. No representation is made as to the safety or effectiveness of these product candidates or the use for which such product

candidates are being studied.Temferon is

an investigational product candidate for which the effectiveness and safety have not been established. In addition, Temferon

is not approved for use in any jurisdiction.

Pollio, Mobile: +39 348 23 15 143